1. Global Initiative for Asthma. Workshop Report, 2006. http://www.ginasthma.com/download.asp?intId=217
2. Глобальная стратегия лечения и профилактики бронхиальной астмы. Под ред. акад. РАМН А.Г.Чучалина. М.: Издательство «Атмосфера», 2002; 1–160.
3. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392–7.
4. Barnes PJ. Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids. Respir Med 2001; 95(Suppl B): S12–S16.
5. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002; 19: 182–91.
6. Bateman ED, Boushey HA, Bousquet J et al. Pedersen SE for the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gain-ing Optimal Asthma Control Study. Am J Respir Crit Care Med 2004; 170: 836–44.
7. Boulet LP, Cartier A, Ernst P et al. Safety and efficacy of HFA-134a be-clomethasone dipropionate extrafine aerosol over six months. Can Respir J 2004; 11: 123–30.
8. Bousquet J, Dell'Anna C. Modulite technology in the development of for-moterol HFApMDI: clinical evidence and future opportunities. Expert Rev Resp Med 2008; 2 (1): 27–36.
9. Dhillon S, Keating GM. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler. Drugs 2006; 66: 1475–83.
10. Mariotti F, Poli G, Acerbi D et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic and COPD patients. Eur Res Congr 2008. Abstract book: Poster P649.
11. Kips JC, O'Connor BJ, Inman MD et al. A long-termed study of the anti-inflammatory effect of low-dosed budesonide plus formoterol versus high-dosed budesonide in asthma. Am Respir Crit Care Med 2000; 161: 996–1001.
12. Lewis DA, Ganderton D, Meakin BJ, Brambilla G. Modulite:a simple so-lution to a difficult problem. Respiration 2005; 72 (Suppl. 1): 3e5.
13. Mak JCW, Nishikawa M, Shirasaki H et al. Protective effects of a gluco-corticoid on downregulation of pulmonary β2-adrenergic receptors in vivo. J Clin Invest 1995; 96: 99–106.
14. Mitchell C, Jenkins C, Scicchitano R et al. Formoterol (Foradil®) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulmon Pharmacol Ther 2003; 16: 299–306.
15. Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM. Beclometha-sone/formoterol vs fluticasone/salmeterol inhaled combinationin moderate to se-vere asthma. Allergy 2007; 62: 1182–8.
16. Papi A, Paggiaro PL, Nicolini G et al. Bеclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 2007; 29: 682–9.
17. Pauwels RA, Lofdahl CG, Posthma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Estab-lishing Therapy (FACET) International Study Group N Engl J Med 1997; 337: 1405–11.
18. Pauwels RA, Sears NR, Cambell M et al. Formoterol as relie medication in asthma: a world safety and effectiveness trial. Eur Respir J 2003; 22: 787–94.
19. Tattersfield AE, Lofdahl C-G, Postma DS et al. Comparison of for-moterol and terbutaline for as-needed treatment of asthma: a randomised controlled trial. Lancet 2001; 357: 257–61.
20. Rigamonti E, Kottakis I, Pelc M et al. Comparison of a new extra-fine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma. Eur. Respir J 2006; 28 (Suppl. 50): 206s.
21. van Noord JA, Smeets JJ, Raaijmakers JA et al. Salmeterol versus for-moterol in patients withmoderately severe asthma: onset and duration of action. Eur Respir J 1996; 9: 1684–8.
22. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addi-tion of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respit Care Med 1996; 153: 1481–8.